Pfizer and BioNTech Update COVID-19 Vaccine Supply Agreement with EC
The companies have reached an agreement with the European Commission to update their COVID-19 vaccine supply agreement.
Pfizer and BioNTech announced on May 13, 2022 that they have reached an agreement with the European Commission (EC) to update their COVID-19 vaccine supply agreement. The update includes rephased planned deliveries to help support the EC and Member States’ immunization programs.
Doses that were scheduled for delivery in June through August 2022 will now be delivered in September through fourth quarter 2022. The delivery schedule change does not affect the companies’ full-year 2022 revenue guidance or the full-year commitment of doses to be delivered to the EC Member States in 2022.
The companies are continuing to evaluate potential variant-based vaccines and expect to share data in the coming months. The Pfizer-BioNTech COVID-19 vaccine is currently authorized under Emergency Use Authorization in individuals five years of age and older.
Source: Pfizer
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
